In a randomized, double-blind, placebo-controlled trial about the effect of albumin on survival after an episode of HE, despite the higher survival observed in the albumin group, albumin failed to increase 90-day transplant-free survival in patients with cirrhosis combined with HE (91.9% vs. 80.5%, p = 0.3); competitive risk analysis of the data obtained observed 90-day cumulative mortality of 9% in the albumin group compared to 20% in the placebo group (p = 0.1) [39]. Here, ALB is linked to Cirrhosis.